Several Duke Cancer representatives were thrilled to join the founders of the I’m Not Done Yet Foundation, an important partner with DCI’s Teen and Young Adult Oncology Program, to ring the opening bell at Nasdaq on Friday, Oct. 7.

Ernest Mario, PhD, and his family, through the Mario Family Foundation, recently made an important new gift that builds upon their past support and will nurture innovation in health care and patient experience for years to come.

Duke University researchers have developed an RNA-based editing tool that targets individual cells, rather than genes. It is capable of precisely targeting any type of cell and selectively adding any protein of interest. Researchers said the tool could enable modifying very specific cells and cell functions to manage disease.

Duke Health leadership launched Translating Duke Health in 2017 as a multi-disciplinary, multi-year commitment to capitalize on Duke’s collective strengths in research, clinical care, and popul

Two Duke professors are among just eight scholars nationwide who have been awarded prestigious Pioneer Awards this year from the National Institutes of Health (NIH).  

Lee Zou, PhD, has been named the new chair of the Department of Pharmacology and Cancer Biology. He will begin his new role on Feb. 1, 2023.

Brittany Davidson, MD, associate professor in the Department of OB-GYN, Division of Gynecologic Oncology, and the director of gynecologic oncology fellowships, shares how she and her colleagues are approaching goal planning, palliative care, and end-of-life ovarian cancer care.

Raphael Valdivia, PhD, has been named chair of the Department of Immunology, effective Oct. 1, 2022. Dr. Valdivia is the Nanaline H.

A new model to predict the life expectancy of older people relies less on their specific disease diagnoses and more on factors such as the ability to grocery shop, the amount of certain small cholesterol particles circulating in their blood, and whether they never or only occasionally smoked.

Families affected by Pompe disease gathered at Duke recently to celebrate the remarkable advances generated by Duke researchers that have helped people with the disease live longer and enjoy a better quality of life. Genetic specialists at Duke developed the only FDA-approved treatment for Pompe disease and continue to work on treatments to give even more patients and families a brighter future.